Abu Dhabi’s Mubadala Investment Company has acquired an 80 percent stake in both Global Medical Supply Chain and Al Ittihad Drug Store from GlobalOne Healthcare Holding, the healthcare division of UAE-based Yas Holding. GlobalOne Healthcare Holding will retain a 20 percent stake in each company. This acquisition enhances Mubadala’s footprint in healthcare logistics and pharmaceutical distribution, marking a significant move in the UAE’s growing healthcare sector. The financial details of the deal have not been disclosed.

Global Medical Supply Chain offers comprehensive supply chain services for medical products, including demand planning, procurement, logistics, inventory management, warehousing, and maintenance. Serving over 200 medical facilities across the UAE, the company plays a crucial role in ensuring the efficient delivery of medical products. Al Ittihad Drug Store specializes in distributing more than 1,000 pharmaceutical and consumer healthcare products from over 40 suppliers. These products span a wide range of therapeutic categories, including anti-infectives, asthma, diabetes, and oncology.

This acquisition is in line with Mubadala’s strategy to address the growing demand for specialized and efficient drug logistics solutions, driven by the expanding pharmaceutical market. Ismail Ali Abdulla, executive director of UAE clusters at Mubadala’s UAE investments platform, emphasized the increasing need for optimized logistics in the healthcare industry, especially in a region with such rapid growth.

Low Ping, group CEO at Yas Holding, expressed that the transaction strengthens Mubadala’s commitment to the UAE’s healthcare and pharmaceutical sectors, supporting the nation’s broader goals of drug security and economic diversification. This deal also reflects Mubadala’s continued efforts to foster a resilient and sustainable healthcare ecosystem within the UAE.

Earlier in March, Mubadala signed a definitive agreement to acquire Kelix Bio, a specialty pharmaceutical business focusing on delivering complex generics across emerging markets. The healthcare sector in the GCC is expected to experience robust growth, with Alpen Capital forecasting healthcare spending will reach $135.5 billion by 2027, representing an annual growth rate of 5 percent from $104 billion in 2023. This underscores the increasing importance of investments in healthcare infrastructure and pharmaceutical services across the region.